Skip to main content
. 2023 Feb 7;12(4):321–338. doi: 10.1159/000529574

Fig. 1.

Fig. 1.

ABC conversion: Patient flow. Atezolizumab followed by curative conversion was performed in 39 patients. Of them, 35 patients achieved clinical complete response (CR) defined by CR per mRECIST and normalized 3 tumor markers ≥6 weeks. Clinical CR with drug-free status was achieved 25 of 38 patients.